Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5477 - Impact of Intralesional Interleukin 2 (IL2) for In-transit Melanoma in two Canadian Centres

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

D Scott Ernst

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

D.S. Ernst1, V. Hayward2, H. McConkey3, X. Teng4, E. Saettler5, T. Cheng6, C. Temple-Oberle7, F. Gwadry-Sridhar8

Author affiliations

  • 1 Dept Of Oncology, London Regional Cancer Program, N6A4L6 - London/CA
  • 2 Dept Of Surgery, University of British Columbia, V1W 4V5 - Kelowna/CA
  • 3 Research Coordinator, Global Melanoma Research Network, N6C 2R6 - London/CA
  • 4 Data Science, Pulse Infoframe Inc., London/CA
  • 5 Dept Of Surgery, Western University, London/CA
  • 6 Dept Of Oncology, University of Calgary, Calgary/CA
  • 7 Dept Of Surgery, University of Calgary, Calgary/CA
  • 8 Dept Computer Science, Western University, London/CA
More

Resources

Abstract 5477

Background

In-transit (IT) melanoma is a form of metastatic disease that is associated with high morbidity and is often refractory to treatment. Intralesional (IAL) IL2 has been increasingly utilized to obtain loco-regional control. This study utilizes a national registry to evaluate response and duration of response of standardized IAL therapy at tertiary centres in 2 provinces.

Methods

Patients (pts) receiving IAL IL2 between 2000 and 2017 were included. Data regarding patient demographics, stage, extent of disease, and all treatments were collected. All pts received a median IL2 dose of 12 million IU given as an IAL injection every 2 to 4 weeks repeated 2 to 8 times to complete a session.

Results

A total of 87 pts aged 21 to 94 (mean: 69 yrs) were included. IT disease was located in the following areas: limbs in 68 pts (79%), head and neck in 13 pts (15%) and trunk in 5 pts (6%). 20% of pts developed IT within 3 months of primary diagnosis, 69% developed IT after 6 months and 11% after 3 years. IT lesions per individual ranged from 1 to 40+; 45% had >10 lesions. Patients had a complete response rate of 32% (28 pts) and a partial response rate of 38% (33 pts). 27 (31%) pts experienced a recurrence after their 1st IL2 session, with a mean of 225 days (median: 204). Of these pts, 15 (56%) pts developed loco-regional recurrences, while 6 (22%) developed distant metastases and 6 (22%) had both distant and loco-regional recurrences. 27 pts (31%) received systemic treatment for metastatic disease. 18 (21%) pts died of disease, while 3% died of other causes while disease was present. 7 (8%) died of other causes with disease status unknown, and 25 (29%) and 34 (39%) are recorded alive with more than a year (1 to 11 yrs) or less than a year follow up, respectively. No grade 3 or 4 toxicity was experienced by pts who received IL2 therapy. On multi-variant analysis, age, extent of disease and prior systemic therapy did not impact overall response (X2 test, p > 0.05).

Conclusions

IAL IL2 appears to be an effective therapeutic option for pts with advanced melanoma and IT disease, with an overall response rate of 70%. With further long-term follow up of these pts, the impact on overall survival can be determined.

Clinical trial identification

Legal entity responsible for the study

Global Melanoma Research Network.

Funding

Global Melanoma Research Network.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings